Back

Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights

European Heart Journal

7 October 2021
Organised by: Logo
Read full article
ESC Journals HEART FAILURE Chronic Heart Failure PREVENTIVE CARDIOLOGY Risk Factors and Prevention

Contributors

Naveed Sattar
Naveed Sattar

Author

University of Glasgow Glasgow , United Kingdom of Great Britain & Northern Ireland

Stefan D Anker
Stefan D Anker

Author

Charite University Hospital Berlin , Germany

Javed Butler
Javed Butler

Author

Subodh Verma
Subodh Verma

Author

St. Michael's Hospital Toronto , Canada

You may be interested in
thumbnail
Congress Presentation
What we have learned from SGLT2i trials
23 May 2023
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Session
The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital
17 May 2025
thumbnail
Congress Session
When and how to treat obesity in heart failure
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources